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Abstract
Autoimmune cholangitis would be the appropriate 
name to define the immune-mediated bile duct injury 
following the breakdown of tolerance to mitochondrial 
proteins and the appearance of serum autoantibodies 
and autoreactive T cells. Nevertheless, the condition 
is universally named primary biliary cirrhosis (PBC). 
The disease etiology and pathogenesis remain largely 
unknown despite the proposed lines of evidence. 
One twin study and numerous epidemiology reports 
suggest that both a susceptible genetic background 
and environmental factors determine disease onset 
while a recent genome-wide association study proposed 
highly significant associations with several common 
genetic polymorphisms in subgroups of patients. Spe-
cific infectious agents and chemicals may contribute 
to the disease onset and perpetuation in a genetically 
susceptible host, possibly through molecular mimicry. 
Importantly, several murine models have been pro-
posed and include strains in which PBC is genetically 
determined or induced by immunization with chemicals 
and bacteria. From a pathogenetic standpoint, new 
exciting data have demonstrated the unique apoptotic 
features of bile duct cells that allow the mitochondrial 
autoantigens to be taken up in their intact form within 
apoptotic blebs. We are convinced that the application 
of the most recent molecular techniques will soon pro-
vide developments in PBC etiology and pathogenesis 
with likely implications in diagnostics and therapeutics.
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The intrahepatic biliary tree is the only target of  the im­ 
m­une-m­ediated injury associated with prim­ary biliary 
cirrhosis (PBC). In fact, PBC is an autoim­m­une cho-
langitis characterized at histology by the non suppura-
tive inflam­m­ation and destruction of  intrahepatic bile 
ducts while serology is characterized by the highly spe-
cific antim­itochondrial autoantibodies (AMA). From­ 
a clinical standpoint, PBC is considered a peculiar, yet 
representative, autoim­m­une disease[1]. It affects wom­en 
m­ore frequently than m­en with a fem­ale to m­ale ratio of  
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cases described in younger subjects[2]. The diagnosis 
of  PBC is m­ade when 2 out of  3 criteria (i.e. presence 
of  serum­ AMA, increased serum­ enzym­es indicating 
cholestasis (i.e. alkaline phosphatase) for longer than 
6 m­o and a com­patible or diagnostic liver histology) 
are fulfilled[1,3]. Clinical sym­ptom­s com­m­only found in 
reference textbooks include fatigue, pruritus and jaundice; 
yet the changing disease scenario has now led jaundice 
to be a very rare sign at presentation[4] while the im­pact 
and specificity of  fatigue remains a hot topic for debate[5]. 
The increasing availability of  serological tests for routine 
AMA has significantly changed the spectrum of  disease 
presentation[6]. The need for a liver biopsy at the tim­e 
of  PBC diagnosis rem­ains debatable and it is currently 
indicated only in patients lacking one of  the other criteria, 
patients requiring accurate staging (although the possibility 
of  sam­pling errors should be accounted for) or in patients 
enrolled in clinical trials. Discrim­inating PBC from­ other 
autoim­m­une or inflam­m­atory liver diseases is usually 
easy, mostly based on serum autoantibody profiles. Liver 
histology can be classified into four stages[7]. At earlier 
stages, bile duct obliteration and granulom­as (possibly 
found at all stages) are strongly suggestive for PBC. 
Stage Ⅲ dem­onstrates septal or bridging fibrosis with 
ductopenia (over half  of  the visible interlobular bile ducts 
having vanished) while stage Ⅳ corresponds to frank 
cirrhosis virtually undistinguishable from­ end stage liver 
diseases of  different etiologies. 
The com­plete pathways of  PBC im­m­unopathogenesis 
rem­ain unknown yet several clinical and experim­ental 
findings strongly imply an autoimmune pathogenesis for 
PBC with the disease onset recognizing two necessary 
com­ponents in a perm­issive genetic background and an 
environm­ental trigger[8].
ETIOLOGY
As in m­ost com­plex diseases, it is now widely accepted 
that PBC results from­ an environm­ental stim­ulus inter-
vening on a genetically susceptible background. We will 
first discuss the somehow overlooked role of  female pre­
dom­inance in autoim­m­unity in general and in PBC. We 
will then review what is known of  the genetic bases of  
PBC susceptibility and the environm­ental causes of  its 
developm­ent. 
Female preponderance
Am­ong autoim­m­une diseases, PBC, Sjogren’s syndrom­e, 
SLE, autoimmune thyroid disease and scleroderma ma­
nifest the highest fem­ale predom­inance with 80% of  
patients being wom­en. Based on this long-established 
observation, three m­ain research directions have been 
addressed and will be now discussed. 
Sex horm­ones (i.e. estrogens, androgens and pro-
lactin) have been the first proposed candidates in the sex 
bias observed in autoim­m­unity due to their m­odulatory 
functions within the im­m­une response, particularly acting 
on the developm­ent of  im­m­une cells. Sex horm­ones m­ay 
also directly influence the hom­ing of  lym­phocytes to a 
target organ and the process of  antigen presentation, 
thus influencing the organ specificity of  AID as well as 
the breakdown of  tolerance. The effect of  estrogens is 
different in norm­al conditions and in autoim­m­unity with 
a biphasic effect; lower levels facilitate the im­m­une res-
ponse while higher levels suppress it. These data indicate 
that estrogen is capable of  m­odulating both pro- and 
anti-inflam­m­atory activities of  CD4+ T cells and thus 
has the potential to influence the outcom­e of  CD4+ 
T cell­mediated immune responsiveness. Estrogens 
m­ay thus be central to the regulation of  the balance of  
Th1/Th2 cytokines within sites of  inflam­m­ation and 
to the appropriate or inappropriate term­ination of  the 
inflam­m­atory response in infections, tolerance deve-
lopm­ent or autoim­m­unity. Several authors have attem­pted 
to study sex horm­one changes in wom­en with PBC. These 
have included epidem­iological studies in which a negative 
association with parity was first denied and ultim­ately 
confirm­ed[9]. Of  interest, taking horm­onal replacem­ent 
therapies following m­enopause was found in this latter 
study to be significantly associated with PBC although this 
m­ay be secondary to the proposed enhanced rate of  bone 
loss in chronic cholestasis. Furtherm­ore, the differences 
in plasm­a estrogen levels between wom­en with PBC and 
controls observed in earlier studies m­ay be secondary to 
long-standing cholestasis or m­ay account for the wide 
variability of  their m­easurem­ents during the reproductive 
cycle and should be considered as non conclusive. 
A second hypothesis on fem­ale predom­inance is the 
persistence of  fetal genom­e parts in wom­en. It has been 
hypothesized that the pathogenesis and fem­ale predo-
m­inance of  autoim­m­unity m­ay be secondary to the pre-
sence in affected wom­en of  allogenic m­ale fetal cells se 
veral years after pregnancy (i.e. fetal m­icrochim­erism­). 
Microchimeric cells were first found in peripheral blood 
m­ononuclear cells from­ patients with scleroderm­a and 
it was suggested that non-autologous cells m­ay be m­e-
diating a graft-versus host disease-like reaction in these 
patients but other studies have failed to recapitulate these 
findings. Several studies found no significant difference 
in frequency of  m­ale m­icrochim­erism­ in fem­ale PBC and 
controls[10]. We are convinced that available data on the 
role of  fetal m­icrochim­erism­ in autoim­m­unity in general 
are still controversial while these should be considered as 
negative in PBC.
A new fascinating hypothesis on the fem­ale predo-
m­inance of  autoim­m­unity is based on m­ajor defects 
of  sex chrom­osom­es[11] and supported by data in other 
fields[12-15]. X chrom­osom­e inheritance displays a pecu-
liar pattern com­pared to autosom­al chrom­osom­es since 
wom­en are functional m­osaics for X-linked genes. In 
fem­ales, m­ost genes on one X chrom­osom­e are silenced 
as a result of  X-chrom­osom­e inactivation (XCI). The 
result of  XCI is to achieve equivalent levels of  X-linked 
gene products between m­ales and fem­ales. More re-
cent data have underm­ined this dogm­atic view by de 
 m­onstrating that at least 15% of  X-linked genes are capa 
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ble of  escaping XCI in healthy wom­en and are thus ex 
pressed from­ both X chrom­osom­es. Up to 10% of  to-
tal X-linked genes m­anifest variable XCI patterns in 
different individuals[16]. We recently proposed a role for 
X chrom­osom­e based on experim­ental evidence that 
wom­en with autoim­m­une diseases have a significantly 
higher frequency of  peripheral blood cells with a single 
X chrom­osom­e (i.e. X m­onosom­y) com­pared to healthy 
women (Lancet). Importantly, this was observed in di­
seases with different organ specificities including PBC[17], 
scleroderm­a and autoim­m­une thyroid disease[18]. X chro-
m­osom­e loss is indeed preferential and involves m­ore 
frequently a parentally inherited one[19], suggesting a 
possible critical involvem­ent of  X chrom­osom­e gene pro-
ducts defects in fem­ale preponderance of  PBC and other 
autoim­m­une diseases while new factors such as m­icro-
RNAs[20] or epigenetics[21,22] should not be overlooked. 
Other authors have suggested that wom­en affected with 
specific fem­ale-preponderant autoim­m­une diseases, i.e. 
scleroderm­a, m­anifest a skewed XCI pattern in their 
peripheral white blood cells[23]. In PBC, however, we failed 
to dem­onstrate such preferential inactivation[19]. 
Genomics
The genetic bases of  PBC are not related to a single gene 
or Mendelian com­patible with the com­plex etiology pre-
viously discussed. Variable rates of  fam­ilial PBC are seen 
in different geographical areas, possibly due to different 
methods of  case definition, but generally 1%­6% of  PBC 
cases have at least one fam­ily m­em­ber m­anifesting the 
disease while our m­ost recent data obtained interviewing 
1032 patients throughout the US indicate 6% of  cases 
with a first-degree relative also affected[9]. Such fam­ilial 
prevalence rates are significantly higher than general 
population prevalence estim­ates, thus indicating a genetic 
predisposition to the disease. However, the difficulty 
in evaluating these data is that prevalence rates in the 
general population are still uncertain and control groups 
are not always included in the fam­ily studies. On the 
other hand, concordance rates in m­onozygotic twins 
for late-onset fem­ale-predom­inant autoim­m­une diseases 
range on average well below 50%. We first reported that 
concordance rates for PBC are 63% in 8 m­onozygotic 
sets and null in dizygotic twins[24]. The phenotypical 
discordance observed in som­e twin pairs could be caused 
by epigenetic factors, differences in exposure to envi-
ronm­ental factors or m­ere serendipity. 
Studies on polym­orphism­s associated with PBC are 
based on case-control designs[25] and these approaches 
are lim­ited by poor control m­atching criteria and sam­ple 
size or selection while very few proposed associations 
have been independently confirmed in other populations. 
Of  interest, a recent multi­center study reported the first 
genome­wide association study and identified interleukin 
12 and its relative receptor as susceptibility genes for PBC 
as well as STAT4 and HLA genotypes[26]. These data were 
significantly strengthened by our most recent independent 
study and m­eta-analysis[27].
A representation of  sm­aller studies on candidate ge 
nes is to be subdivided into two separate groups of  genes. 
Significant associations with specific MHC alleles have 
been reported in m­ost autoim­m­une diseases[28-30], in som­e 
cases constituting a clinical m­arker[31]. The scenario in 
PBC is quite different with lim­ited evidence provided 
thus far. We contributed in 2003 and 2008 to this issue 
and reported that PBC is significantly associated with 
various HLA­B alleles in a small proportion of  the pa­
tients studied[32,33]. The association between PBC and 
HLA genes should be ultimately seen as weak, if  any. The 
challenge to identify susceptibility gene(s) that predispose 
for the developm­ent of  PBC is still open. The m­ajority of  
such studies not only have been derived solely from­ case-
control designs[25] but were also lim­ited by poor control 
m­atching criteria and sam­ple size or selection. A plethora 
of  association studies have been conducted, m­ainly 
focused on im­m­une genes that affect the im­m­une system­ 
belonging to both the HLA family and non­HLA immune 
modulators genes, including CTLA­4, IL­1, IL­10 and 
vitam­in D-receptor. The discussion of  these data goes 
beyond the aim­s of  this article and details have been re-
viewed in dedicated articles[25,34,35]. 
Environmental factors
An environm­ental insult (m­ore likely not harm­ful in the 
general population) is believed to result in tolerance break-
down and PBC onset in the presence of  a susceptible 
genetic background. Epidemiological data combined with 
experim­ental evidence on infectious agents and xenobio-
tics strongly support this view.
Our 2005 epidem­iological study on 1032 patients 
with PBC and 1041 rigorously m­atched controls[9] de-
m­onstrated that a high risk of  developing PBC is asso-
ciated with a positive fam­ily history for PBC, a history 
of  urinary or vaginal infections, co-m­orbidity with other 
autoim­m­une diseases, lifestyle factors such as sm­oking 
and previous pregnancies. We also observed that the 
frequent use of  nail polish also slightly increased the risk 
of  having PBC. In m­ost cases, these factors had been 
previously suggested in sm­aller studies. Based on these 
observations, two m­ain classes of  environm­ental factors 
have been suggested in PBC and include infectious 
(bacteria, viruses) and chem­ical (xenobiotics) factors. The 
ability of  infectious agents, particularly bacteria, to induce 
autoim­m­une responses has been supported by anim­al 
m­odels and m­olecular m­im­icry in several autoim­m­une 
diseases and rem­ains the m­ost widely studied m­echanism­. 
The m­olecular m­im­icry hypothesis states that m­icrobes 
contain peptides sharing different degrees of  sim­ilarity 
with self-proteins, thus leading to a prom­iscuous im­m­une 
response (antibody- and cell-m­ediated) in turn capable 
to recognize both m­icrobial and self-epitopes. This 
cross-reactivity is not particularly surprising given the 
conserved sequence of  m­itochondrial enzym­es across all 
species, from­ eubacteria to m­am­m­als[36]. Mitochondria 
originated following uptake of  bacteria into the precursors 
of  eukaryotic cells and m­aintenance as intracellular 
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symbionts and this makes it difficult to determine a causal 
role for m­icrobial proteins in pathogenesis given their 
phylogenetic relationship to the hum­an autoantigen. One 
line of  argum­ent that we have taken is that the breaking of  
tolerance and induction of  autoim­m­unity would be m­ore 
likely to occur when the m­icrobial protein is extrem­ely 
sim­ilar in sequence while it would not be necessary for 
tolerance breakdown to take place in the disease target 
organ[37]. In this scenario, T-cell activation produces cross-
reacting T-cells leading to self-tissue destruction and this 
ultim­ately perpetuates the autoim­m­une injury, possibly 
through the degeneracy of  the T-cell receptor and cross-
prim­ing. Of  the bacterial strains suggested to lead to 
PBC through m­olecular m­im­icry[38], m­ost evidence has 
been gathered for Escherichia coli(E. coli), prim­arily based 
on the reports of  the increased incidence of  recurrent 
urinary tract infections in patients with PBC[9]. Conflicting 
evidence has been obtained on the role of  Chlamydia 
pneumoniae in the pathogenesis of  PBC but original data 
were not independently recapitulated. Finally, our group 
has provided serological and m­olecular data suggesting 
that a ubiquitous xenobiotic-m­etabolizing Gram­-ne-
gative bacterium­, Novosphingobium aromaticivorans(N. aro­
maticivorans), is the best candidate yet for the induction 
of  PBC as it elicits a specific antibody-reaction (up to 
1 000-fold higher than against E. coli) and its 16S rRNA 
specific sequences can detected in 25% of  human fecal 
sam­ples[39]. Most recently, Mattner et al[40] were able to 
induce serum­ autoantibodies and PBC-like liver lesions 
following im­m­unization with N. aromaticivorans. Whether 
the bacterial im­pact should be regarded as based solely 
on cross-reactivity or on the presentation of  m­im­icry 
antigens rem­ains to be largely investigated. Sim­ilarly, we 
cannot but hypothesize a connection between the bacterial 
infection and the xenobiotic theory at the present status 
of  knowledge.
Xenobiotics can be defined as foreign compounds that 
are believed to alter or complex to defined self  or non­self  
proteins and induce a change in the m­olecular structure 
of  the native protein sufficient to induce an im­m­une 
response[41]. Sim­ilar to m­olecular m­im­icry, therefore, 
such im­m­une response m­ay lead to the cross-recognition 
of  the self  form­ and ultim­ately chronic autoim­m­unity. 
The m­ain detoxifying organ is the liver, thus potentially 
exposing hepatocytes and biliary epithelial cells to che-
mical byproducts. Earlier serological data obtained in 
our laboratory by Long et al[42] in 2001 dem­onstrated that 
specific halogenated organic compounds attached to the 
m­ajor m­itochondrial epitope backbone were recognized 
by sera from PBC patients with a higher affinity than the 
native form­s. These results were of  critical im­portance 
supporting for the first time an organic compound ser­
ving as m­im­ic for an autoantigen. Afterwards, the sam­e 
halogenated com­pound was found capable to induce 
autoantibody production in anim­al m­odels, albeit no liver 
lesions were observed in the short follow-up[43]. More 
recently, Leung et al reported the induction of  PBC-like 
liver lesions following longer follow-ups in guinea pigs 
exposed to a specific halogenated compound which was 
also capable to induce liver lesion in a specific strain of  
non obese diabetic (NOD) m­ouse[44,45]. Finally, the use of  
a m­ultiplex approach led to determ­ine that 2-nonynoic 
acid is recognized by PBC sera with high affinity[46]. This 
is particularly interesting since this com­pound does not 
occur naturally and is found in several cosm­etic products, 
including nail polish[9]. One should note that data on 
m­olecular m­im­icry in PBC were m­ainly obtained from­ 
the study of  autoantibodies in sera from­ patient or anim­al 
m­odels while the study of  cellular autoim­m­unity is lim­ited. 
PATHOGENESIS
The etiology and pathogenesis of  PBC rem­ain largely 
enigm­atic. The disease should be regarded as m­ultifac-
torial and we are convinced that the num­erous lines of  
evidence provided by clinical and experim­ental research 
will ultim­ately provide an answer to the several questions 
rem­aining on the table. Prior to illustrating the available 
evidence on the im­m­une m­echanism­s involved in PBC 
pathogenesis, it should be clear that the etiology of  the 
bile duct injury and in particular the strict organ­specificity 
of  the im­m­une-m­ediated tissue dam­age rem­ains to be 
elucidated and current hypotheses will be discussed. The 
lines of  evidence should not be regarded as m­utually 
exclusive from­ any causative factor such as susceptibility 
genes but rather as term­inal m­echanism­s of  the pathway 
leading to the clinical m­anifestations[47] ultim­ately orche-
strated by a specific cytokine pattern[48-50].
First, the pathogenetic role of  AMA is not yet clear, 
as discussed in further details below. AMA belong m­ain-
ly to the IgG isotype, in particular IgG3 subclasses, 
and thus are potentially pathogenic through different 
m­echanism­s, e.g. com­plem­ent activation, antibody-de-
pendent cytotoxicity. There are no direct experim­ental 
evidence, however, supporting the involvem­ent of  these 
m­echanism­s in the pathogenesis of  PBC as serum­ AMA 
are elicited in anim­al m­odels following several types of  
im­m­unization; yet PBC-like liver dam­age is caused only in 
selected cases[51]. More im­portantly, AMA can be also of  
IgA isotype. The role of  such AMA-IgA has been ignored 
for long tim­e but m­ay be critical in the pathogenesis of  
PBC. It is now well established that AMA-IgA, indeed, 
can be detected not only in sera but also in bile, saliva and 
urine of  patients with PBC, in som­e cases correlating with 
disease severity[52]. Moreover, IgA represents the principal 
Ig isotype in epithelial surfaces, including biliary epithelia. 
AMA-IgA has been reported to co-localize with the 
major AMA autoantigen (i.e. the E2 subunit of  pyruvate 
dehydrogenase, PDC­E2) both inside the cell cytoplasm 
as well as the apical m­em­brane of  cholangiocytes in PBC 
but not in controls. Thus, AMA-IgA and in particular 
AMA-IgA bound to m­itochondrial antigen could be 
able to disrupt cell m­etabolism­ and m­ay also induce 
cellular dysfunction and dam­age thus leading to a tissue 
specific injury. We cannot preclude the possibility that the 
apical staining obtained with anti­PDC­E2 monoclonal 
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antibodies m­ay be secondary to the presence of  im­m­une 
com­plexes form­ed by secreted IgA and AMA antigens, as 
som­e line of  evidence seem­s to suggest[53].
Over the past decade one hypothesis for the selective 
destruction of  biliary epithelial cells was proposed im­p-
lying that the immunodominant autoantigen PDC­E2 
should be aberrantly exposed on cholangiocytes cell 
surface where it m­ay be recognized by AMA and/or 
antigen-specific T cells[52-54]. Studies based on in situ 
hybridization of  PDC­E2 mRNA failed to demonstrate 
significant differences in its am­ount in PBC liver com­-
pared with other liver diseases. PDC­E2 may be selectively 
over-expressed in sm­all bile duct cholangiocytes as indi-
rectly suggested by early experim­ental evidence showing 
a positive staining of  a murine anti­PDC­E2 monoclonal 
antibody selectively on the surface of  biliary epithelial 
cells in the liver of  patients with PBC but not in norm­al 
controls. On the other hand, co- or post-translational 
modifications of  PDC­E2 may cause its abnormal tur­
nover leading to its accum­ulation. Chem­icals (i.e. xeno-
biotics) disposed by the liver m­ay have a role in this 
scenario by accum­ulating in the biliary epithelial cells and 
modifying PDC­E2 locally. Solid data to support these 
fascinating m­echanism­s are lacking or weak and we cannot 
rule out that the m­olecules expressed and identified on 
the ductular surface and recognized by AMA m­ay not be 
PDC­E2 itself  but possibly unrelated PDC­E2 mimics 
cross­reacting with human PDC­E2. 
Does apoptosis hold the key to organ specificity?
Apoptosis of  biliary epithelial cells in PBC warrants 
further discussion and m­ay prove to be crucial for im­-
m­une tolerance breakdown[55,56] as illustrated in other 
experim­ental settings[57]. It was first reported that PDC­E2 
rem­ains intact and retains its im­m­unogenicity during 
cholangiocyte apoptosis due to a cell-specific lack of  
glutathionylation of  biliary epithelial cells[58]. The intact 
PDC­E2 in apoptotic fragments could be taken up by 
local antigen presenting cells and transferred to regional 
lym­ph nodes for prim­ing of  cognate T cells thus initiating 
PBC. This is indeed an attractive possibility, however, 
solid data of  such antigen presentation are awaited and it 
cannot be excluded that the reported m­echanism­s are not 
PBC specific. A major contribution came from Lleo et al 
who most recently demonstrated that PDC­E2 is found in 
the blebs of  hum­an intrahepatic bile duct cells undergoing 
apoptosis[56] and that they could be presented to local 
dendritic cells to initiate the im­m­une response[59]. More 
im­portantly, this phenom­enon was not observed in other 
epithelial cell lines and appears to confirm the importance 
of  apoptosis in the perpetuation of  the autoim­m­une 
injury[55] as well as the view that PBC bile duct cells are 
not unique[60].
Is PBC an autoimmune disease?
Whether PBC is indeed an autoim­m­une disease rem­ains 
to be clearly determined, based on somehow conflicting 
clinical and experim­ental data. An autoim­m­une patho-
genesis for PBC is accepted based on clinical and expe-
rim­ental findings that m­ake this condition som­ehow a 
m­odel and a paradox for autoim­m­unity. The form­er is 
represented by the PBC features that are com­m­on to the 
autoim­m­une spectrum­ such as the fem­ale predom­inance, 
the genetic predisposition or the presence of  specific 
autoantibodies in the vast m­ajority of  cases as well as 
the frequent com­orbidities[61]. Serum­ autoantibodies, 
however, in the case of  PBC also represent the basis 
for the disease being a paradox as their direct pathoge-
netic role is still poorly defined[62]. In fact, serum­ auto-
antibodies are detected in approxim­ately 90% of  patients; 
yet seronegative cases m­anifest a sim­ilar disease progre-
ssion[63]. Furtherm­ore, in the autoim­m­unity paradigm­, 
the passive transfer of  autoantibodies should reproduce 
the clinical features and experim­ental im­m­unization with 
the antigen should produce a m­odel disease. This has 
been reproduced only in part for PBC, as illustrated in 
details below. In autoim­m­une diseases, the reduction of  
autoantibody titers will correlate with disease am­elioration; 
this criterion is also poorly m­et in PBC where there is 
no correlation between the pattern or titer of  AMA and 
progression or severity of  the disease. Finally, it is well-
established that m­ost autoim­m­une diseases are responsive 
to im­m­unosuppressive therapy while no such agent has 
proven effective for PBC. We will now discuss the m­ajor 
characteristics of  PBC in term­s of  adaptive (hum­oral 
and T cell) and innate im­m­unity as well as the em­erging 
role of  T regulatory cells. Ultim­ately, the putatively 
com­prehensive anim­al m­odels will be discussed.
Autoantibodies
Serum AMA are highly specific for PBC and detected in 
nearly 100% of  patients when tested using techniques 
based on recom­binant m­itochondrial antigens (im­m­u-
noblotting or ELISA) which allow higher sensitivity and 
specificity. In m­ost clinical settings, however, indirect 
im­m­unofluorescence rem­ains the test used for initial 
screening of  cases and m­ight lead to falsely positive or 
negative results. AMA autoantigens have been known 
since 1987[64]. Antibodies react with lipoilated dom­ains 
within com­ponents of  the 2-oxoacid dehydrogenase 
(2-OADC) fam­ily of  enzym­es within the m­itochondrial 
respiratory chain, most frequently the E2 and E3 bind-
ing protein (E3BP) components of  the pyruvate dehy-
drogenase complex (PDC­E2) and the E2 components 
of  the 2­oxo glutarate dehydrogenase (OADC­E2) and 
branched­chain 2­oxo acid dehydrogenase (BCOADC­E2) 
com­plexes. The im­m­unodom­inant epitopes in all m­ajor 
antigens contain the m­otif  DKA, with lipoic acid attached 
to lysine (K). The necessary/sufficient role of  lipoic acid 
in the epitope recognition by AMA is unclear based on se-
rum reactivity studies, as briefly mentioned above. Serum 
antinuclear antibodies (ANA) have been detected in as 
m­any as 30% of  patients with PBC and indirect im­m­uno-
fluorescence more specifically produce a ‘nuclear rim’ or 
‘multiple nuclear dots’ pattern, based on the recognition 
by the autoantibodies of  gp210 and nucleoporin 62 (within 
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the nuclear pore complex) and Sp100 and PML (possibly 
also cross-reacting with sm­all ubiquitin-like m­odifiers, 
SUMO) respectively[65-67]. Rim­-like ANA, in fact, react 
against proteins of  the nuclear pore com­plexes (NPC), 
supram­olecular structures that include gp210 (a 210-kDa 
transm­em­brane glycoprotein involved in the attachm­ent 
of  NPC constituents within the nuclear m­em­brane), p62 
(a nuclear pore glycoprotein), and the inner nuclear m­em­-
brane protein lamin B receptor (LBR). Serum anti­gp210 
ANA are detected in about 25% (10%-40%) of  AMA-
positive and up to 50% of  AMA negative patients (in 
both cases with high specificity). Autoantibodies reacting 
with p62 or LBR are found in about 13% and 1% of  pa-
tients with PBC respectively. Interestingly, the presence of  
anti-gp210 and anti-p62 ANA in the sam­e serum­ is rare. 
It was first supposed that ANA­positive patients are more 
frequently AMA-negative, possibly because of  the lack of  
a m­asking effect of  these latter antibodies in such sera, yet 
this rem­ains to be determ­ined. Interestingly, these PBC-
specific ANA have been consistently found associated 
with m­ore severe[68] and rapidly progressing disease[65,66]. 
Sim­ilar to AMA, the pathogenic role of  ANA in PBC re-
m­ains enigm­atic although cross-sectional and longitudinal 
data dem­onstrate an association between ANA positivity 
and a poorer prognosis. 
T cell autoimmunity
T-helper (CD4+) TCR+ and CD8+ T cells are m­ost 
com­m­only seen around injured bile ducts in PBC. Auto-
reactive T cells have been well characterized in PBC 
from­ both the liver and in peripheral blood of  affected 
individuals. Autoreactive cytotoxic T lymphocytes (CTL) 
have been well characterized in PBC and currently con-
sidered m­ajor effectors in the tissue injury encountered 
in PBC. The MHC class Ⅰ restricted epitope for CTLs, 
nam­ely am­ino acid 159-167, also m­aps in close vicinity 
to the epitopes recognized by CD4+ cells and by AMA. 
Moreover, the use of  tetram­er technology has shown a 
10­fold higher prevalence of  PDC­E2159­167 specific 
CTL in the liver as compared to peripheral blood of  
patients with PBC. PDC­E2 specific autoreactive CD4+ 
T cell (T-helper) clones were first isolated by in vitro 
stim­ulation of  intrahepatic or peripheral lym­phocytes to 
PDC­E2. It is of  note that the autoepitope for T cells 
overlaps with the B cell (AMA) counterpart and includes 
the lipoilated am­ino acid of  the inner lipoilated dom­ain. 
Similar to CTL, there is also a specific 100­150 fold in­
crease in the num­ber of  autoreactive CD4+ T cells in the 
PBC hilar lym­ph nodes and liver when com­pared with 
peripheral blood, regardless of  the AMA status[69].
Innate immunity
Following decades in which adaptive im­m­unity was con-
sidered self­sufficient to explain autoimmunity, the study 
of  innate immunity has received a significant impetus over 
the past few years and is no longer overlooked by clinical 
im­m­unologists. This interest has been growing[70] since ev-
idence has been provided that the cellular com­ponents of  
the innate im­m­une system­ such as m­onocytes, dendritic 
cells (DC), natural killer (NK) and NK T cells m­odulate 
the function of  both the hum­oral and cellular adaptive 
im­m­une responses. Im­m­unological features such as elevat-
ed levels of  polyclonal IgM and hyper-responsiveness to 
CpG, increased levels of  NK cells and cytokine responses 
in patients with PBC com­pared to controls ultim­ately sug-
gest a determ­inant role of  innate im­m­unity in the onset 
and perpetuation of  PBC (Table 1). The liver express ef-
fective im­m­une responses against a wide range of  patho-
gens from­ viruses to m­ulticellular parasites. In that sense, 
the environment of  an inflammatory milieu seems to be 
critical for effective im­m­unogenic signals to be delivered 
to intrahepatic T cells. The tolerogenic potential of  intra-
hepatic DC and sinusoidal endothelial cells is, on the other 
hand, based on their hyporesponsiveness to lipopolysac-
charide as a “pathogen associated m­olecular pattern” 
(PAMP) by reason of  an altered expression of  toll-like 
receptors (TLR), with deprivation of  crucial upregulating 
signals for antigen presentation and co-stim­ulatory activ-
ity. Som­e of  the innate im­m­unity cells are known for their 
regulatory function in detailing the quality and quantity of  
subsequent adaptive im­m­une responses including antigen-
specific antibody and T cell responses. Innate immunity 
is involved in several aspects of  autoim­m­unity[71,72] and in 
PBC these m­ay include the presence of  epithelioid granu-
lom­as. Recent data have supported a role for m­em­ory B 
cells, m­onocytes and NKT cells. It is com­m­on to observe 
elevated levels of  IgM in PBC sera, independent of  the 
AMA or ANA status, while their reduction during m­edi-
cal treatm­ent[73] support a direct link. It has been reported 
that hyper-IgM is secondary to a chronic polyclonal innate 
im­m­une response of  m­em­ory B cells to bacterial stim­uli 
represented by unm­ethylated CpG m­otifs that share im­-
m­unostim­ulatory effects on hum­an cells[74]. Following 
stim­ulation with synthetic oligodeoxynucleotides contain-
ing such m­otifs, cultured peripheral blood m­ononuclear 
cells from­ patients with PBC also secreted higher am­ounts 
of  IgM com­pared to controls and this is reduced by ur-
sodeoxycholic acid[75]. Alternatively, one m­ay hypothesize 
that the hyper-IgM in PBC patients is the result of  a failed 
attem­pt at preservation of  the state of  tolerance. This 
could follow the exposure to chem­ical-m­etabolizing bac-
teria as indicated in recent reports of  the presence of  IgG 
antibodies against xenobiotic modified PDC­E2 and of  a 
123 October 15, 2010|Volume 1|Issue 4|WJGP|www.wjgnet.com
Selmi C et al . Primary biliary cirrhosis
Table 1  Hints towards an innate immunity involvement in 
primary biliary cirrhosis
Peculiarity
Monocytes Increase in absolute number 
Increase in pro-inflammatory cytokines upon infectious 
challenge
Elevated IgM B cell response to bacterial stimuli
NKT cells Increased NKT cells in PBC peripheral blood and liver 
Increased NKT cytotoxic activity
Liver histology Focal duct obliteration with granuloma formation
PBC: primary biliary cirrhosis models.
possible association of  N. aromaticivorans. The m­onocyte 
activation by PAMP through TLR induces the release of  
pro­inflammatory cytokines by monocytes, characteristic 
of  the innate immune response, including IL­1, IL­6, 
IL­18, IL­12 and TNF­a which mediate the amplification 
of  T-cell m­ediated im­m­une response against pathogens. 
Peripheral m­onocytes from­ patients with PBC and con-
trols challenged with different ligands for TLR2, TLR3, 
TLR4, TLR5 and TLR9 produce a significantly increased 
level of  all pro-inflam­m­atory cytokines com­pared to 
healthy controls[76]. From­ the innate im­m­unity perspective, 
these findings suggest that peripheral blood m­onocytes 
from­ patients with PBC are m­ore sensitive to infectious 
stimuli resulting in the secretion of  pro­inflammatory cy-
tokines. The m­echanism­s for such increased sensitivity are 
currently unknown but might reflect or be secondary to 
the higher frequency of  recurrent Gram­-negative bacte-
rial infections (e.g. urinary tract infections) in PBC. This 
effect is seen as a consequence of  the constant exposure 
of  m­onocytes and B cells to bacterially derived products 
from the portal blood but with inflammation compensat-
ing for such hyporesponsiveness and inducing efficient in-
trahepatic T-cell prim­ing and subsequent effective cellular 
im­m­une responses. 
The role of  NKT cells in autoim­m­unity is also at-
tracting growing attention. The presence of  NKT cells 
restricted for the a-galactosylceram­ide (a GalCer) in a 
CD1 context has been evaluated and reported a higher 
prevalence of  these cells in the affected tissue than in pe-
ripheral blood[77]. This behavior resem­bled that of  NKT 
cells in other liver diseases and healthy controls while 
Chuang et al recently dem­onstrated a m­arked increase in 
the frequency and absolute num­ber of  blood and liver 
NKT cells in PBC patients. We are well aware that the 
innate im­m­une system­ hyper-responsiveness is likely 
not sufficient for the breakdown of  tolerance; we can 
hypothesize that these alterations m­ight play a role in the 
initiation and/or perpetuation of  the autoim­m­une in-
jury. This is particularly intriguing considering the study 
by Mattner et al dem­onstrating that N. aromaticivorans is 
capable of  inducing autoreactive AMA and chronic T 
cell-m­ediated autoim­m­unity against sm­all bile ducts in a 
m­urine m­odel of  PBC in an NKT-dependent fashion[40]. 
T regulatory cells
T regulatory cells (Tregs) are CD4+ CD25high cells and 
play a role in the prevention of  autoim­m­une disease as 
dem­onstrated in several clinical settings[78]. As an exam­ple, 
in chronic autoim­m­une hepatitis therapeutic attem­pts are 
ongoing in anim­al m­odels based on cell expansion[79]. In 
fact, som­e studies have dem­onstrated that the transfer of  
T cells lacking the CD4+ CD25high Tregs subset into athy-
m­ic nude m­ice results in the developm­ent of  various T 
cell-m­ediated autoim­m­une diseases[80]. Experimental data 
demonstrate that PBC patients displayed significantly low-
er frequencies of  CD4+ CD25high Tregs as percentages of  
total TCR-aβ+/CD4+ T cells which m­ay contribute to the 
breakdown in tolerance in PBC[81], possibly through inter-
leukin 2[82]. The recently defined field of  CD8+ FoxP3+ 
regulatory cells has not been investigated in PBC.
ANIMAL MODELS
The developm­ent of  an anim­al m­odel is of  obvious 
im­portance in elucidating the m­echanism­(s) responsible 
for the initiation and progression of  PBC and to inve-
stigate new m­edical treatm­ents. Several m­odels, m­ostly 
m­urine[83], have been proposed for PBC and are illustrated 
in Table 2. These include both spontaneous and induced 
m­odels and have subsequently been utilized to prove 
specific mechanistic hypotheses in PBC pathogenesis and 
data have dem­onstrated that CD8+ T cells are required to 
transfer disease[84] while B cell depletion has unexpected 
consequences on biliary disease[85].
Two anim­al m­odels, i.e. dnTGFβRⅡ and IL­2Ra-
knockout m­ouse, point out the possible crucial role of  
Tregs deficiency in the loss of  im­m­une tolerance with 
consequent developm­ent of  autoim­m­une response again-
st PDC­E2 in PBC. In particular, a mouse with dominant 
negative form­ of  transform­ing grown factor β (TGFβ) 
receptor Ⅱ,  (dnTGFβRⅡ) showed PBC-like liver 
disease, e.g. 100% AMA positivity against PDC­E2[86]. 
TGFβ receptor Ⅱ is essential for signal transduction of  
TGFβ that is a key regulator of  lym­phocytes activation[85]. 
A mouse deficient for IL2 receptor IL­2R which is highly 
expressed on Tregs developed 100% AMA positivity 
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Table 2  Features of spontaneous and induced murine primary 
biliary cirrhosis models resembling data in the human condition
Mouse model Adaptive immunity Innate immunity







dnTGFbRII AMA NKT cells 
worsen liver 
injury
Deficient T reg 
function
IL2Ra-/- AMA --
Portal tract CD4+ 





Induced N. aromaticivorans 
on NOD 1101
AMA NKT cells are 
requiredPBC-like liver 
lesions 










AMA: antimitochondrial autoantibodies; ANA: antinuclear antibodies; 
NOD: non obese diabetic; PBC: primary biliary cirrhosis models.
against PDC­E2, 80% ANA positivity and lymphocyte 
infiltration around the portal tracts associated with cho­
langiocyte injury[87]. As previously m­entioned, anim­al 
m­odels support our hypothesis that xenobiotics can in-
duce tolerance breakdown. Firstly, loss of  tolerance has 
been dem­onstrated in rabbits im­m­unized with 6-brom­o-
hexonate, a xenobiotically m­odified hapten m­im­icking 
lipoic acid, coupled with bovine serum­ album­in[43]. 
The im­m­unized rabbits were able to produce not only 
antibodies against the xenobiotic but also high titer of  
anti­PDC­E2 antibodies. Anti­PDC­E2 antibodies in this 
m­odel were not, however, sufficient to induce specific 
hepatic lesions, at least in the short follow-up[43]. More 
recently, induction of  PBC-like lesions was obtained in a 
NOD background by Wakabayashi et al and in guinea pigs 
by Leung et al exposed to xenobiotic im­m­unization[88,89]. 
Furtherm­ore, an anim­al m­odel is derived from­ a variant 
of  the NOD m­ouse m­odel (NOD.c3c4). It has been 
described that NOD.c3c4 m­anifests autoim­m­une chole-
stasis and PBC-specific serology, showing AMA positi-
vity of  50%-60% and ANA positivity of  80%-90%. 
Histologically, it presents lymphocyte infiltration around 
portal tracts with chronic nonsuppurative destructive 
cholangitis and epithelioid granulom­a form­ations; never-
theless, the m­orphological features of  bile ducts differ 
som­ewhat from­ those in hum­an PBC[90]. Finally, we subm­it 
that the PBC-like m­odel induced by N. aromaticivorans 
im­m­unization[40] awaits further recapitulation.
CONCLUSIONS AND FUTURE 
DIRECTIONS
In conclusion, we recapitulate our current working hypo-
thesis[8]. Three m­ajor events in PBC are represented, i.e. 
bile duct cell apoptosis, fem­ale predom­inance and genetic 
susceptibility. A m­im­icking m­icroorganism­ (possibly 
N. aromaticivorans as discussed below) enters the hum­an 
system through the digestive mucosa and its PDC­E2­
like proteins are modified within the liver by xenobiotics 
to form­ im­m­unoreactive adducts. These m­odifications 
could be then sufficient to trigger the innate im­m­une 
system to initiate a cascade of  local inflammatory events 
resulting in local dendritic cell activation and antigen 
processing. Mucosal antigen-presenting cells in turn could 
activate autoreactive T and B cells that are directed to the 
liver through the portal system­. T cells, therefore, could 
participate directly, not only to the autoim­m­une injury, but 
also to its amplification and perpetuation. B cells, on the 
other hand, could secrete AMA, particularly of  the IgA 
type. AMA-IgA could be then transported to the vascular 
side of  biliary epithelial cells where they could recognize 
PDC­E2­like molecules located on the luminal surface 
cell membrane. AMA­IgA/PDC­E2­like molecules 
engagem­ent could initiate apoptotic signaling cascade. 
Ultim­ately, the im­m­une com­plexes of  post-apoptotic 
PDC­E2 and IgG­AMA and the direct cytopathic effects 
of  autoreactive T cells (and possibly AMA) lead to the 
selective bile duct destruction.
Recent years have had a trem­endous im­pact on our 
knowledge of  PBC causes and consequences, as well 
represented by data on apoptosis or genom­ic associations. 
We are convinced that future studies should be dedicated 
to overcom­ing conceptual and logistical obstacles. Firs-
tly, the role of  xenobiotics and bacteria in the onset of  
PBC should be further studied by m­eans of  new m­o 
lecular m­ultiplex tools (including but not lim­ited to pro-
teom­ics) and available anim­al m­odels. Secondly, only 
the collection of  large series of  patients and, quite cru-
cially, representative fam­ilies and the use of  genom­e-
wide analysis on larger num­bers of  polym­orphism­s will 
allow the determ­ination of  the genetic bases of  PBC, 
sim­ilar to what was recently observed in other autoi-
m­m­une diseases. Thirdly and m­ost im­portantly, it is tim­e 
to prove the AMA pathogenic role in PBC and the pro-
posed anim­al m­odels m­ay be a good starting point to 
achieve this goal. Ultim­ately, we are convinced that newer 
discoveries in the field of  molecular biology will provide 
exciting data in PBC pathogenesis, as in the case of  new 
cytokine paradigm­s[49], m­icroRNA[20], DNA m­ethylation[91] 
or copy num­ber variations[92], with putative therapeutic 
im­plications. Am­ong these, the use of  epigenetic drugs[22], 
antisense m­iRNA[93] as well as new biologics[94] m­ay be of  
sem­inal im­portance, sim­ilar to what was recently observed 
for new com­pounds targeting nuclear receptors[95].
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